vs
因美纳（ILMN）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
因美纳的季度营收约是STANDARD BIOTOOLS INC.的342.6倍（$1.1B vs $3.2M）。STANDARD BIOTOOLS INC.净利率更高（598.5% vs 16.8%，领先581.6%）。STANDARD BIOTOOLS INC.同比增速更快（262.0% vs -1.6%）。因美纳自由现金流更多（$335.0M vs $-1.7M）。过去两年因美纳的营收复合增速更高（0.8% vs -73.4%）
因美纳是总部位于美国加利福尼亚州圣迭戈的生物技术企业，成立于1998年4月，专注研发、生产及销售用于分析基因变异与生物功能的集成系统，产品及服务覆盖测序、基因分型、基因表达、蛋白质组学等领域，业务遍及全球超155个国家和地区。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
ILMN vs LAB — 直观对比
营收规模更大
ILMN
是对方的342.6倍
$3.2M
营收增速更快
LAB
高出263.6%
-1.6%
净利率更高
LAB
高出581.6%
16.8%
自由现金流更多
ILMN
多$336.7M
$-1.7M
两年增速更快
ILMN
近两年复合增速
-73.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $3.2M |
| 净利润 | $186.0M | $19.3M |
| 毛利率 | 65.9% | 83.5% |
| 营业利润率 | 15.8% | -578.6% |
| 净利率 | 16.8% | 598.5% |
| 营收同比 | -1.6% | 262.0% |
| 净利润同比 | 205.7% | 156.6% |
| 每股收益（稀释后） | $1.16 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ILMNLAB
| Q4 25 | — | $3.2M | ||
| Q3 25 | — | $19.6M | ||
| Q2 25 | — | $21.8M | ||
| Q1 25 | — | $40.8M | ||
| Q4 24 | $1.1B | $890.0K | ||
| Q3 24 | $1.1B | $22.1M | ||
| Q2 24 | $1.1B | $22.5M | ||
| Q1 24 | $1.1B | $45.5M |
净利润ILMNLAB
| Q4 25 | — | $19.3M | ||
| Q3 25 | — | $-34.7M | ||
| Q2 25 | — | $-33.5M | ||
| Q1 25 | — | $-26.0M | ||
| Q4 24 | $186.0M | $-34.1M | ||
| Q3 24 | $705.0M | $-26.9M | ||
| Q2 24 | $-2.0B | $-45.7M | ||
| Q1 24 | $-126.0M | $-32.2M |
毛利率ILMNLAB
| Q4 25 | — | 83.5% | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | 65.9% | -202.8% | ||
| Q3 24 | 69.0% | 54.9% | ||
| Q2 24 | 64.8% | 46.1% | ||
| Q1 24 | 62.0% | 53.1% |
营业利润率ILMNLAB
| Q4 25 | — | -578.6% | ||
| Q3 25 | — | -168.5% | ||
| Q2 25 | — | -118.1% | ||
| Q1 25 | — | -80.8% | ||
| Q4 24 | 15.8% | -1162.1% | ||
| Q3 24 | 68.6% | -120.9% | ||
| Q2 24 | -147.2% | -134.5% | ||
| Q1 24 | -10.3% | -132.2% |
净利率ILMNLAB
| Q4 25 | — | 598.5% | ||
| Q3 25 | — | -177.4% | ||
| Q2 25 | — | -153.7% | ||
| Q1 25 | — | -63.8% | ||
| Q4 24 | 16.8% | -3828.3% | ||
| Q3 24 | 65.3% | -122.0% | ||
| Q2 24 | -178.8% | -203.3% | ||
| Q1 24 | -11.7% | -70.6% |
每股收益（稀释后）ILMNLAB
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | $1.16 | $-0.06 | ||
| Q3 24 | $4.42 | $-0.07 | ||
| Q2 24 | $-12.48 | $-0.12 | ||
| Q1 24 | $-0.79 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $93.0M | $120.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $424.3M |
| 总资产 | $6.3B | $567.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ILMNLAB
| Q4 25 | — | $120.9M | ||
| Q3 25 | — | $129.4M | ||
| Q2 25 | — | $158.6M | ||
| Q1 25 | — | $150.9M | ||
| Q4 24 | $93.0M | $166.7M | ||
| Q3 24 | $70.0M | $210.6M | ||
| Q2 24 | $74.0M | $269.8M | ||
| Q1 24 | — | $287.1M |
总债务ILMNLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $299.0K | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益ILMNLAB
| Q4 25 | — | $424.3M | ||
| Q3 25 | — | $399.7M | ||
| Q2 25 | — | $424.5M | ||
| Q1 25 | — | $454.6M | ||
| Q4 24 | $2.4B | $471.7M | ||
| Q3 24 | $2.1B | $489.3M | ||
| Q2 24 | $1.4B | $510.3M | ||
| Q1 24 | $5.7B | $577.3M |
总资产ILMNLAB
| Q4 25 | — | $567.8M | ||
| Q3 25 | — | $539.6M | ||
| Q2 25 | — | $557.0M | ||
| Q1 25 | — | $579.6M | ||
| Q4 24 | $6.3B | $612.3M | ||
| Q3 24 | $6.0B | $681.5M | ||
| Q2 24 | $6.1B | $708.7M | ||
| Q1 24 | $10.0B | $777.7M |
负债/权益比ILMNLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $364.0M | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | $335.0M | $-1.7M |
| 自由现金流率自由现金流/营收 | 30.3% | -51.7% |
| 资本支出强度资本支出/营收 | 2.6% | 14.8% |
| 现金转化率经营现金流/净利润 | 1.96× | -0.06× |
| 过去12个月自由现金流最近4个季度 | $709.0M | $-82.6M |
8季度趋势，按日历期对齐
经营现金流ILMNLAB
| Q4 25 | — | $-1.2M | ||
| Q3 25 | — | $-22.2M | ||
| Q2 25 | — | $-20.7M | ||
| Q1 25 | — | $-30.3M | ||
| Q4 24 | $364.0M | $-14.1M | ||
| Q3 24 | $316.0M | $-27.9M | ||
| Q2 24 | $80.0M | $-39.0M | ||
| Q1 24 | $77.0M | $-62.5M |
自由现金流ILMNLAB
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | — | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q4 24 | $335.0M | $-17.4M | ||
| Q3 24 | $284.0M | $-30.1M | ||
| Q2 24 | $49.0M | $-41.0M | ||
| Q1 24 | $41.0M | $-63.3M |
自由现金流率ILMNLAB
| Q4 25 | — | -51.7% | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | — | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q4 24 | 30.3% | -1959.7% | ||
| Q3 24 | 26.3% | -136.4% | ||
| Q2 24 | 4.4% | -182.2% | ||
| Q1 24 | 3.8% | -138.9% |
资本支出强度ILMNLAB
| Q4 25 | — | 14.8% | ||
| Q3 25 | — | 4.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | 2.6% | 380.0% | ||
| Q3 24 | 3.0% | 10.2% | ||
| Q2 24 | 2.8% | 8.6% | ||
| Q1 24 | 3.3% | 1.7% |
现金转化率ILMNLAB
| Q4 25 | — | -0.06× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.96× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ILMN
| Sequencing | $1.0B | 91% |
| Microarray | $101.0M | 9% |
| Investee | $7.0M | 1% |
LAB
暂无分部数据
